Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-05
DOI
10.1186/s13045-021-01172-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography
- (2021) Wataru Matsumiya et al. American Journal of Ophthalmology Case Reports
- Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
- (2020) Rakesh Popat et al. HAEMATOLOGICA
- Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients
- (2020) Rebecca B. Bausell et al. Eye & Contact Lens-Science and Clinical Practice
- EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
- (2020) Kyriaki Tzogani et al. ONCOLOGIST
- Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery
- (2020) Antoine Rousseau et al. OPHTHALMOLOGY
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Corneal features in trastuzumab emtansine treatment: not a rare occurrence
- (2019) Els Deklerck et al. BREAST CANCER RESEARCH AND TREATMENT
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
- (2018) Hui Zhao et al. CANCER RESEARCH
- Corneal Changes in Trastuzumab Emtansine Treatment
- (2018) Elke O. Kreps et al. Clinical Breast Cancer
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Ocular Toxicity of Mirvetuximab
- (2018) Eleonora Corbelli et al. CORNEA
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Cytosine-Arabinoside-Induced Keratopathy: A Model of Corneal Proliferation Kinetics
- (2010) Tanja Guthoff et al. OPHTHALMOLOGICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started